Nuvation Bio, Inc. is a biopharmaceutical company based in the United States that focuses on addressing unmet needs in oncology through the development of innovative therapeutic candidates. The company's ESG score indicates a medium risk level. One of their key products is NUV-868, an oral small molecule BET inhibitor that targets BRD4 and plays a crucial role in regulating tumor growth and differentiation. In addition, Nuvation Bio is working on a Drug-Drug Conjugate platform, offering a unique approach to anti-cancer therapies. Nuvation Bio, Inc. is a pharmaceutical company in the United States with a focus on oncology treatments. They have a medium risk rating (ESG score) and are known for their innovative therapeutic candidates like NUV-868 and Drug-Drug Conjugate platform.